Skip to main content

Table 1 Pretreatment characteristics of patients included in systematic review

From: Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients

Author

Sample size (ntg/ttg)

Age (years) (ntg/ttg)

PSA level (ng/ml) (ntg/ttg)

Clinical stage (ntg/ttg)

Gleason score (ntg/ttg)

Pilepich 2001 [12]

226/230

No record

No record

T2 to 4

2 to 6 (total: 129), 7 (total: 176), 8 to 10 (total: 124)

Laverdiere 2004 [13]

149/154

Median: 69/68

Median: 9.3/12

T2 (total: 255), T3 (total: 40)

≤6 (total: 223), 7 to 10 (total: 77)

Soloway 1995 [14]

149/154

Mean: 64.9 ± 5.7/65.4 ± 5.9

Median: 14.3/12.5

T2b, NxM0

Mean: 6.1 ± 0.17/5.8 ± 0.16

Denham 2005 [15]

270, 272/276

Median: 68, 68/67

Median: 14.4, 14.6/16.4

T2b (66, 68/72), T2c (88, 94/92), T3 to 4 (111, 105/106)

2 to 6 (117, 122/113), 7 (92, 99/114), 8 to 10 (53, 43/41)

Roach 2008 [5]

224/232

Median: 70/71

Median: 22.6/33.8

T2 to 4

3 to 6 (70/59), 7 to 10 (145/156)

Deham 2011 [6]

265, 267/270

Median: 68, 68/67

Median: 14.4, 14.5/16.4

T2b (67, 68/72), T2c (87, 94/92), T3 to 4 (111, 105/106)

2 to 6 (118, 123/114), 7 (94, 101/115), 8 to 10 (53, 43/41)

Dalkin 1996 [16]

30/31

Median: 65.5/64.7

4.1 to 10 (16/18), 10.1 to 20 (9/9), >20 (3/1)

T1c (17/16), T2a (8/12), T2b (3/0)

2 to 4 (8/6), 5 to 7 (16/21), 8 to 10 (4/1)

Goldenberg 1996 [17]

112/101

Mean: 62.5 ± 6.0/62.2 ± 5.9

0 to 4 (10/13), 4.1 to 10 (45/41), 10.1 to 25 (33/30), 25.1 to 50 (13/7)

T1b (5/4), T1c (5/3), T2a (30/33), T2b (19/17), T2c (42/34)

2 to 4 (2/5), 5 to 7 (82/75), 8 to 10 (15/11)

Labrie 1997 [18]

71/90

Range: 46 to 72

≤10 (67/53), >10 (23/18)

B0 (3/3), B1 (43/39), B2 (29/17), C1 (8/7), C2 (7/5)

No record

Schulman 2000 [9]

192/210

No record

No record

T2 (105/115), T3 (87/95)

No record

Selli 2002 [19]

143, 122/128

Mean: 65.43, 66.16/65.72

Median: 10.15, 10.0/10.20

T2 to 3, N0, M0

2 to 6 (29,2/46), 7 (31,8/1), 8 to 10 (0,11/0)

Soloway 2002 [20]

149/154

Mean: 64.9/65.4

Median: 14.3/12.5

T2b

Mean: 6.1/5.8

Aus 2002 [21]

63/63

Mean: 67/66

Median: 12.0/11.2

T1b to T1c (10/15), T2a (10/10), T2b to T3a (43/38)

2 to 4 (2/1), 5 to 6(26/22), 7 to 10 (35/40)

Klotz 2003 [10]

112/101

Median: 64/63

<10 (61/54), 10 to 20 (32/26), >20 (17/18)

T1b to T1c (12/7), T2a (36/35), T2b (19/21), T2c (41/32)

2 to 6 (75/73), 7(21/17), 8 to 10 (14/8)

Prezioso 2004 [22]

91/93

Mean: 64.9/64.5

<4 (ntg:6), ≥4 < 10 (ntg: 30), ≥10 (ntg: 39)

T1a to T2b

No record

  1. Ntg/ttg, neo-adjuvant therapy group/traditional therapy group; PSA, prostate-specific antigen.